Status:
COMPLETED
Pain Response to Cannabidiol in Opioid-induced Hyperalgesia, Acute Nociceptive Pain and Allodynia By Using a Model Mimicking Acute Pain in Healthy Adults
Lead Sponsor:
University Hospital, Basel, Switzerland
Conditions:
Acute Nociceptive Pain
Hyperalgesia
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Prospective, randomized, placebo-controlled, double-blinded, crossover study to investigate the effect of cannabidiol (CBD) on remifentanil-induced hyperalgesia in healthy volunteers in a well-establi...
Detailed Description
Opioid-induced hyperalgesia (OIH) is a clinically often neglected, but well described phenomenon. OIH could also be shown for Remifentanil in an acute pain model. As CBD showed antihyperalgesic potent...
Eligibility Criteria
Inclusion
- BMI between 18.5 until 25 kg/m2
- Able to give informed consent
Exclusion
- Regular consumption of cannabinoids or other drugs / substances
- Regular intake of medications potentially interfering with pain sensation (analgesics, antihistamines, calcium and potassium channel blockers, serotonin / noradrenaline reuptake inhibitors, corticosteroids)
- Neuropathy
- Chronic pain
- Neuromuscular disease
- Psychiatric disease
- Known or suspected kidney or liver disease
- Pregnancy (cf. 8.6 Trial specific preventive measures) / Lactation
- Allergy / hypersensitivity to cannabidiol
- Contraindications for Remifentanil (e.g. hypersensitivity)
Key Trial Info
Start Date :
May 26 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
October 15 2020
Estimated Enrollment :
21 Patients enrolled
Trial Details
Trial ID
NCT04059978
Start Date
May 26 2020
End Date
October 15 2020
Last Update
October 19 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Department of Anaesthesiology, University Hospital of Basel (USB)
Basel, Switzerland, 4031